Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML)

BCR fused ABL kinase is the critical driving oncogene for chronic myeloid leukemia (CML) and has been extensively studied as the drug discovery target in the past decade. The successful introduction of tyrosine kinase inhibitors (TKI) such as Imatinib, Dasatinib and Bosutinib has greatly improved th...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Biol Ther
Hlavní autoři: Wu, Jiaxin, Wang, Aoli, Li, Xixiang, Chen, Cheng, Qi, Ziping, Hu, Chen, Wang, Wenliang, Wu, Hong, Huang, Tao, Zhao, Ming, Wang, Wenchao, Hu, Zhenquan, Liu, Qingwang, Wang, Beilei, Wang, Li, Li, Lili, Ge, Jian, Ren, Tao, Xia, Ruixiang, Liu, Jing, Liu, Qingsong
Médium: Artigo
Jazyk:Inglês
Vydáno: Taylor & Francis 2019
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6606039/
https://ncbi.nlm.nih.gov/pubmed/30894066
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2019.1579958
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky